Vimarsana
Biggest News Aggregation in the World

Page 37 - Syntax Advisors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Syntax Advisors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Syntax Advisors Today - Breaking & Trending Today

Intuit (NASDAQ:INTU) Posts Earnings Results, Beats Estimates By $0.22 EPS - Vimarsana News

Intuit (NASDAQ:INTU) Posts Earnings Results, Beats Estimates By $0.22 EPS

Intuit (NASDAQ:INTU – Get Free Report) issued its quarterly earnings results on Thursday. The software maker reported $1.65 EPS for the quarter, beating the consensus estimate of $1.43 by $0.22, MarketWatch Earnings reports. Intuit had a net margin of 16.59% and a return on equity of 16.80%. The company had revenue of $2.71 billion during […]

Intuit (NASDAQ:INTU) Issues Quarterly Earnings Results - Vimarsana News

Intuit (NASDAQ:INTU) Issues Quarterly Earnings Results

Intuit (NASDAQ:INTU – Get Free Report) announced its quarterly earnings results on Thursday. The software maker reported $1.65 earnings per share for the quarter, beating the consensus estimate of $1.43 by $0.22, MarketWatch Earnings reports. The firm had revenue of $2.71 billion during the quarter, compared to analyst estimates of $2.64 billion. Intuit had a […]

Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells 19,998 Shares of Stock - Vimarsana News

Insider Selling: Nektar Therapeutics (NASDAQ:NKTR) CEO Sells 19,998 Shares of Stock

Nektar Therapeutics (NASDAQ:NKTR – Get Free Report) CEO Howard W. Robin sold 19,998 shares of the business’s stock in a transaction dated Wednesday, August 16th. The shares were sold at an average price of $0.78, for a total value of $15,598.44. Following the completion of the transaction, the chief executive officer now owns 919,799 shares […]

Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Reaffirmed by Mizuho - Vimarsana News

Nektar Therapeutics (NASDAQ:NKTR) Stock Rating Reaffirmed by Mizuho

Mizuho reissued their neutral rating on shares of Nektar Therapeutics (NASDAQ:NKTR – Free Report) in a research report sent to investors on Monday morning, Benzinga reports. They currently have a $6.00 target price on the biopharmaceutical company’s stock. A number of other research firms also recently issued reports on NKTR. Jefferies Financial Group upgraded shares […]

Source: wkrb13.com
Paramount Global (PARA) Scheduled to Post Quarterly Earnings on Monday - Vimarsana News

Paramount Global (PARA) Scheduled to Post Quarterly Earnings on Monday

Paramount Global (NASDAQ:PARA – Get Free Report) is set to post its quarterly earnings results after the market closes on Monday, August 7th. Analysts expect Paramount Global to post earnings of ($0.01) per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link. […]